{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:43:58Z","timestamp":1760183038565,"version":"build-2065373602"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.rdc.2020.01.013","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T18:50:45Z","timestamp":1587754245000},"page":"367-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Axial Spondyloarthritis in the Era of Precision Medicine"],"prefix":"10.1016","volume":"46","author":[{"given":"Rianne E.","family":"van Bentum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene E.","family":"van der Horst-Bruinsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rdc.2020.01.013_bib1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.01.013_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.013_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2020.01.013_bib4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/1759720X12458372","article-title":"Management and evaluation of extra-articular manifestations in spondyloarthritis","volume":"4","author":"van der Horst-Bruinsma","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7","key":"10.1016\/j.rdc.2020.01.013_bib5","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)","author":"Kroon","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.rdc.2020.01.013_bib6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.rdc.2020.01.013_bib7","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2020.01.013_bib8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2020.01.013_bib9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/kex361","article-title":"What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both?","volume":"57","author":"Poddubnyy","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2020.01.013_bib10","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2020.01.013_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.013_bib12","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.013_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2020.01.013_bib14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.semarthrit.2011.05.003","article-title":"Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review","volume":"41","author":"Cruz Fernandez-Espartero","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2020.01.013_bib15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Gotestam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2020.01.013_bib16","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00296-015-3288-z","article-title":"Dose reduction of biological treatment in patients with axial spondyloarthritis in clinical remission: Are there any differences between patients who relapsed and to those who remained in low disease activity?","volume":"35","author":"Almirall","year":"2015","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.rdc.2020.01.013_bib17","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","article-title":"Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review","volume":"55","author":"Navarro-Compan","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.013_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratacos","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.rdc.2020.01.013_bib19","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1136\/annrheumdis-2014-205213","article-title":"Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24\u00a0weeks of follow-up","volume":"74","author":"Kneepkens","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2020.01.013_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2013-204185","article-title":"Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24\u00a0weeks of follow-up","volume":"74","author":"Kneepkens","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2020.01.013_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/03009742.2015.1114666","article-title":"Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients","volume":"45","author":"Marsman","year":"2016","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2020.01.013_bib22","first-page":"2568","article-title":"The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27","volume":"32","author":"Linssen","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.013_bib23","first-page":"26","article-title":"Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients","volume":"37","author":"Frantz","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2020.01.013_bib24","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2020.01.013_bib25","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1136\/annrheumdis-2014-205358","article-title":"A\u00a0novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool)","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2020.01.013_bib26","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.ophtha.2016.03.010","article-title":"Description and prevalence of spondyloarthritis in patients with anterior uveitis: the SENTINEL interdisciplinary collaborative project","volume":"123","author":"Juanola","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.rdc.2020.01.013_bib27","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2003.07.011","article-title":"Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases","volume":"111","author":"Monnet","year":"2004","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.rdc.2020.01.013_bib28","first-page":"2198","article-title":"Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis","volume":"27","author":"Pato","year":"2000","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2020.01.013_bib29","first-page":"584","article-title":"Complications of uveitis: the Northern California Epidemiology of Uveitis Study","volume":"26","author":"Gritz","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"10.1016\/j.rdc.2020.01.013_bib30","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3899\/jrheum.170115","article-title":"The effect of anterior uveitis and previously undiagnosed spondyloarthritis: results from the DUET cohort","volume":"44","author":"O'Rourke","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2020.01.013_bib31","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s10067-018-4249-1","article-title":"Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis","volume":"37","author":"Kim","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2020.01.013_bib32","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/eye.2008.198","article-title":"Methotrexate: an option for preventing the recurrence of acute anterior uveitis","volume":"23","author":"Munoz-Fernandez","year":"2009","journal-title":"Eye (Lond)."},{"issue":"6","key":"10.1016\/j.rdc.2020.01.013_bib33","first-page":"1277","article-title":"Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period","volume":"30","author":"Munoz-Fernandez","year":"2003","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2020.01.013_bib34","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00417-018-4082-x","article-title":"The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study","volume":"256","author":"Zu Hoerste","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.rdc.2020.01.013_bib35","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2020.01.013_bib36","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2020.01.013_bib37","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3899\/jrheum.131289","article-title":"Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis","volume":"41","author":"van Denderen","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2020.01.013_bib38","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rdc.2020.01.013_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3899\/jrheum.180312","article-title":"Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab: the GO-EASY study","volume":"46","author":"van Bentum","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2020.01.013_bib40","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A\u00a0fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.rdc.2020.01.013_bib41","article-title":"Reduction of anterior uveitis flares in patients with axial spondyloarthritis following 1 year of treatment with certolizumab pegol: 48-week interim results from a 96-week open-label study [abstract]","volume":"71","author":"van der Horst-Bruinsma","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2020.01.013_bib42","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2020.01.013_bib43","doi-asserted-by":"crossref","first-page":"471319","DOI":"10.1155\/2014\/471319","article-title":"Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept","volume":"2014","author":"Raffeiner","year":"2014","journal-title":"Case Rep Med"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.013_bib44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2020.01.013_bib45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.rdc.2020.01.013_bib46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A\u00a0systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.rdc.2020.01.013_bib47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s100670200097","article-title":"Disease manifestations and HLA antigens in psoriatic arthritis in northern Sweden","volume":"21","author":"Alenius","year":"2002","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2020.01.013_bib48","first-page":"586","article-title":"HLA antigens in psoriatic arthritis","volume":"13","author":"Gladman","year":"1986","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.013_bib49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.rdc.2020.01.013_bib50","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2020.01.013_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/ard.57.3.135","article-title":"Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis?","volume":"57","author":"Helliwell","year":"1998","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2020.01.013_bib52","first-page":"2577","article-title":"Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire","volume":"29","author":"Alenius","year":"2002","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2020.01.013_bib53","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris: update 2015--short version--EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.rdc.2020.01.013_bib54","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/jdv.14454","article-title":"European S3-Guideline on the systemic treatment of psoriasis vulgaris: update apremilast and secukinumab--EDF in cooperation with EADV and IPC","volume":"31","author":"Nast","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.rdc.2020.01.013_bib55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.rdc.2019.07.002","article-title":"Treat to target in psoriatic arthritis","volume":"45","author":"Zhang","year":"2019","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"10.1016\/j.rdc.2020.01.013_bib56","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2020.01.013_bib57","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?","volume":"62","author":"Baeten","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"11\u201312","key":"10.1016\/j.rdc.2020.01.013_bib58","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.rdc.2020.01.013_bib59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2020.01.013_bib60","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","article-title":"Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy","volume":"8","author":"Rahier","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.rdc.2020.01.013_bib61","first-page":"40","article-title":"A\u00a0case of palmoplantar pustulosis induced by certolizumab pegol: new anti-TNF-alpha demonstrates the same class effect","volume":"5","author":"Shelling","year":"2012","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2020.01.013_bib62","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jbspin.2007.06.011","article-title":"Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy","volume":"75","author":"Wendling","year":"2008","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.rdc.2020.01.013_bib63","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","article-title":"The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series","volume":"8","author":"Afzali","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"issue":"7","key":"10.1016\/j.rdc.2020.01.013_bib64","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/annrheumdis-2014-205253","article-title":"The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2020.01.013_bib65","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model","volume":"72","author":"Van Praet","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.013_bib66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/art.1780370105","article-title":"High frequency of silent inflammatory bowel disease in spondyloarthropathy","volume":"37","author":"Leirisalo-Repo","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2020.01.013_bib67","first-page":"2279","article-title":"The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint","volume":"22","author":"Mielants","year":"1995","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2020.01.013_bib68","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1053\/gast.1996.v110.pm8964393","article-title":"Long-term evolution of gut inflammation in patients with spondyloarthropathy","volume":"110","author":"De Vos","year":"1996","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.rdc.2020.01.013_bib69","first-page":"2860","article-title":"Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association","volume":"27","author":"de Vlam","year":"2000","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2020.01.013_bib70","first-page":"330","article-title":"[Enteropathic spondylarthritis in chronic inflammatory bowel diseases: prevalence, manifestation pattern and HLA association]","volume":"91","author":"Protzer","year":"1996","journal-title":"Med Klin (Munich)"},{"issue":"10\u201311","key":"10.1016\/j.rdc.2020.01.013_bib71","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1080\/00365521.2018.1518482","article-title":"Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study","volume":"53","author":"Ossum","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.013_bib72","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ecco-jcc\/jjx126","article-title":"Ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: results from 20 years of follow-up in the IBSEN Study","volume":"12","author":"Ossum","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"issue":"3","key":"10.1016\/j.rdc.2020.01.013_bib73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/00365521.2014.966753","article-title":"Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease","volume":"50","author":"Kvasnovsky","year":"2015","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1016\/j.rdc.2020.01.013_bib74","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1542-3565(05)00980-8","article-title":"Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease","volume":"4","author":"Takeuchi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.rdc.2020.01.013_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004800.pub2","article-title":"Sulfasalazine for ankylosing spondylitis","author":"Chen","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.rdc.2020.01.013_bib76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2020.01.013_bib77","first-page":"44","article-title":"Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis","volume":"55","author":"Chitul","year":"2017","journal-title":"Rom J Intern Med"},{"issue":"12","key":"10.1016\/j.rdc.2020.01.013_bib78","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.rdc.2020.01.013_bib79","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","article-title":"Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials","volume":"76","author":"Reich","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X20300132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X20300132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:18:20Z","timestamp":1760181500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X20300132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0889857X20300132"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2020.01.013","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axial Spondyloarthritis in the Era of Precision Medicine","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2020.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}